ducovest

IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 59.76

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.84M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

N/A

 USD 40.46B
FHLC Fidelity® MSCI Health Care In..

N/A

 USD 2.91B
FXH First Trust Health Care AlphaD..

N/A

 USD 1.19B
XHE SPDR® S&P Health Care Equipme..

N/A

 USD 0.22B
IDNA iShares Genomics Immunology an..

N/A

 USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

N/A

 USD 0.13B
XHS SPDR® S&P Health Care Service..

N/A

 USD 0.08B
HTEC Robo Global® Healthcare Techn..

N/A

 USD 0.06B
BBP Virtus LifeSci Biotech Product..

N/A

 USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

N/A

 USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

N/A

 N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.39% 62% D 45% F
Dividend Return 0.92% 69% C- 15% F
Total Return 5.31% 67% D+ 36% F
Trailing 12 Months  
Capital Gain 11.43% 24% F 50% F
Dividend Return 1.31% 61% D- 15% F
Total Return 12.74% 24% F 43% F
Trailing 5 Years  
Capital Gain 45.34% 95% A 69% C-
Dividend Return 7.52% 72% C 20% F
Total Return 52.86% 95% A 65% D
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 71% C- 57% F
Dividend Return 7.59% 76% C+ 53% F
Total Return 0.99% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 18.55% 57% F 59% D-
Risk Adjusted Return 40.94% 71% C- 58% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike